Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > CHECK out ONC.TO Cancer breakthrough?

<< Previous

Bullboard Posts

Next >>

Comment by Goaweighon Feb 17, 2021 1:05pm

128 Views

Post# 32585722

RE:RE:RE:CHECK out ONC.TO Cancer breakthrough?

No problem, there is definately a right way and a wrong way to co-list and I've seen them both.
Getting your market ( buyers ) lined up and watching before delivering good news is important.
You put bums in the seats before you start the show, not the other way around.

The trick is to time all of these events so they happen seamlessly but if you can pull it off the reward can be significant.
Think this group has a well thought out plan so we wait for the execution.

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario